Treating elderly people with diabetes and stages 3 and 4 chronic kidney disease

Clinical Journal of the American Society of Nephrology

Volumn 3, Issue 4, 2008, Pages 1185-1194

  Abaterusso, Cataldo ^a   Lupo, Antonio ^a   Ortalda, Vittorio ^a   de Biase, Vincenzo ^a   Pani, Antonello ^b   Muggeo, Michele ^a   Gambaro, Giovanni ^a  

^a UNIVERSITY HOSPITAL OF VERONA   (Italy)

^b BROTZU HOSPITAL   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

AGE; AGED; AGING; CARDIOVASCULAR DISEASE; CHRONIC DISEASE; DIABETIC NEPHROPATHY; DISEASE COURSE; HOSPITALIZATION; HUMAN; MIDDLE AGED; MULTIMODALITY CANCER THERAPY; NON INSULIN DEPENDENT DIABETES MELLITUS; PATIENT SELECTION; PRACTICE GUIDELINE; QUALITY OF LIFE; REVIEW; TREATMENT OUTCOME;

AGE FACTORS; AGED; AGED, 80 AND OVER; AGING; CARDIOVASCULAR DISEASES; CHRONIC DISEASE; COMBINED MODALITY THERAPY; DIABETES MELLITUS, TYPE 2; DIABETIC NEPHROPATHIES; DISEASE PROGRESSION; HUMANS; MIDDLE AGED; PATIENT SELECTION; PRACTICE GUIDELINES AS TOPIC; QUALITY OF LIFE; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 49149129988     PISSN: 15559041     EISSN: 1555905X     Source Type: Journal    
DOI: 10.2215/CJN.00410108     Document Type: Review

References (69)

1. European Diabetes Working Party for Older People: Clinical Guidelines for Type 2 Diabetes Mellitus, 2004. Available at: http://www.eugms.org/ index.php?pid=30. Accessed January 8, 2008
2. Brown AF, Mangione CM, Saliba D, Sarkisian CA: California Healthcare Foundation/American Geriatrics Society Panel on Improving Care for Elders with Diabetes. Guidelines for improving the care of the older person with diabetes mellitus. J Am Geriatr Soc 51 [Suppl Guidelines]: S265-S280, 2003
3. Morgan CL, Currie CJ, Peters JR: Relationship between diabetes and mortality: A population study using record linkage. Diabetes Care 23: 1103-1107, 2000
4. US Renal Data System: USRDS 2007 Annual Data Report: Atlas of End-Stage Renal Disease in the United States, Bethesda, National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases. Available at: http://www.usrds.org/2007/view/ 02_incid_prev.asp. Accessed December 31, 2007
5. KDOQI clinical practice guidelines and clinical practice recommendations for diabetes and chronic kidney disease. Am J Kidney Dis 49: S1-S179, 2007
6. Wenger NS, Shekelle PG, Roth CP, the ACOVE investigators: Introduction to the Assessing Care of Vulnerable Elders-3 Quality Indicator Measurement Set. J Am Geriatr Soc 55[Suppl 2]: S247-S252, 2007
7. De Ferrari G, Italian Society of Nephrology: Guidelines for diagnosis and therapy of diabetic nephropathy. G Ital Nefrol 20[Suppl 24]: S96-S108, 2003
8. Caring for Australians with Renal Impairment. Available at: http:// www.cari.org.au/ckd_prevent_list_published-.php. Accessed January 8, 2008
9. Report of the experts of the ALFEDIAM (French Language Association for the Study of Diabetes and Metabolic Diseases) and SFN. Management of end-stage renal failure in diabetic patients. Short text [in French]. Diabetes Metab 26: 81-87, 2000
10. International Diabetes Federation: Clinical Guidelines Task Force. Global Guidelines for Type 2 Diabetes. Kidney Damage, 2005 Available at: http://www.idf.org/webdata/docs/IDF%20GGT2D.pdf. Accessed January 8, 2008
11. Patel UD, Young EW, Ojo AO, Hayward RA: CKD progression and mortality among older patients with diabetes. Am J Kidney Dis 46: 406-414, 2005
12. Gullion CM, Keith DS, Nichols GA, Smith DH: Impact of comorbidities on mortality in managed care patients with CKD. Am J Kidney Dis 48: 212-220, 2006
13. US Renal Data System: USRDS 2003 Annual Data Report: Chapter One, Chronic Kidney Disease: first-year mortality rates, by CKD and diabetic status. Available at: http://www.usrds.org/2003/slides/html/ 01_ckd_03_files/frame.htm. Accessed January 8, 2008
14. Joly D, Anglicheau D, Alberti C, Nguyen AT, Touam M, Grunfeld JP, Jungers P: Octogenarians reaching end-stage renal disease: Cohort study of decision-making and clinical outcomes. J Am Soc Nephrol 14: 1012-1021, 2003
15. Muggeo M, Verlato G, Bonora E, Ciani F, Moghetti P, Eastman R, Crepaldi G, de Marco R: Long-term instability of fasting plasma glucose predicts mortality in elderly NIDDM patients: The Verona Diabetes Study. Diabetologia 38: 672-679, 1995
16. UK Prospective Diabetes Study (UKPDS) Group: Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 352: 837-853, 1998
17. Abraira C, Colwell JA, Nuttall FQ, Sawin CT, Nagel NJ, Comstock JP, Emanuele NV, Levin SR, Henderson W, Lee HS: Veterans Affairs Cooperative Study on Glycemic Control and Complications in Type II Diabetes (VA CSDM): Results of the feasibility trial. Veterans Affairs Cooperative Study in Type II Diabetes. Diabetes Care 18: 1113-1123, 1995
18. Shekelle P, Vijan S. ACOVE: Quality indicators for the care of diabetes mellitus in vulnerable elders. J Am Geriatr Soc 55[Suppl 2]: S312-S317, 2007
19. Krepinsky J, Ingram AJ, Clase CM: Prolonged sulfonylurea-induced hypoglycemia in diabetic patients with end-stage renal disease. Am J Kidney Dis 35: 500-505, 2000
20. Charpentier G, Riveline JP, Varroud-Vial M: Management of drugs affecting blood glucose in diabetic patients with renal failure. Diabetes Metab 26[Suppl 4]: 73-85, 2000
21. Ben-Ami H, Nagachandran P, Mendelson A, Edoute Y: Drug-induced hypoglycemic coma in 102 diabetic patients. Arch Intern Med 159: 281-284, 1999
22. Balant L, Zahnd G, Gorgia A, Schwarz R, Fabre J: Pharmacokinetics of glipizide in man: Influence of renal insufficiency. Diabetologia 9: 331-338, 1973
23. Schumacher S, Abbasi I, Weise D, Hatorp V, Sattler K, Sieber J, Hasslacher C: Single- and multiple-dose pharmacokinetics of repaglinide in patients with type 2 diabetes and renal impairment. Eur J Clin Pharmacol 57: 147-152, 2001
24. Nissen SE, Wolski K: Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med 356: 2457-2471, 2007
25. Singh S, Loke YK, Furberg CD: Long-term risk of cardiovascular events with rosiglitazone: A meta-analysis. JAMA 298: 1189-1195, 2007
26. Lincoff AM, Wolski K, Nicholls SJ, Nissen SE: Pioglitazone and risk of cardiovascular events in patients with type 2 diabetes mellitus: A meta-analysis of randomized trials. JAMA 298: 1180-1188, 2007
27. Budde K, Neumayer HH, Fritsche L, Sulowicz: W, Stompor T, Eckland D: The pharmacokinetics of pioglitazone in patients with impaired renal function. Br J Clin Pharmacol 55: 368-374, 2003
28. Schneider CA, Ferrannini E, Defronzo R, Schernthaner G, Yates J, Erdmann E: Effect of pioglitazone on cardiovascular outcome in diabetes and chronic kidney disease. J Am Soc Nephrol 19: 182-187, 2008
29. Agrawal A, Sautter MC, Jones NP: Effects of rosiglitazone maleate when added to a sulfonylurea regimen in patients with type 2 diabetes mellitus and mild to moderate renal impairment: A post hoc analysis. Clin Ther 25: 2754-2764, 2003
30. Riddle MC, Rosenstock J, Gerich J, Insulin Glargine 4002 Study Investigators: The treat-to-target trial: Randomized addition of glargine or human NPH insulin to oral therapy of type 2 diabetic patients. Diabetes Care 26: 3080-3086, 2003
31. Tonelli M, Bohm C, Pandeya S, Gill J, Levin A Kiberd BA: Cardiac risk factors and the use of cardioprotective medications in patients with chronic renal insufficiency. Am J Kidney Dis 37: 484-489, 2001
32. Chantrel F, Enache I, Bouiller M, Kolb I, Kunz K, Petitjean P, Moulin B, Hannedouche T: Abysmal prognosis of patients with type 2 diabetes entering dialysis. Nephrol Dial Transplant 14: 129-136, 1999
33. Huang ES, Meigs JB, Singer DE: The effect of interventions to prevent cardiovascular disease in patients with type 2 diabetes mellitus. Am J Med 111: 633-642, 2001
34. Brenner BM, Cooper ME, de Zeeuw D, Keane WF, Mitch WE, Parving HH, Remuzzi G, Snapinn SM, Zhang Z, Shahinfar S, RENAAL Study Investigators: Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 345: 861-869, 2001
35. Lewis EJ, Hunsicker LG, Clarke WR, Berl T, Pohl MA, Lewis JB, Ritz E, Atkins RC, Rohde R, Raz I, Collaborative Study Group: Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 345: 851-860, 2001
36. Strippoli GF, Craig M, Decks JJ, Schena FP, Craig JC: Effects of angiotensin converting enzyme inhibitors and angiotensin II receptor antagonists on mortality and renal outcomes in diabetic nephropathy: Systematic review. BMJ 329: 828-838, 2004
37. UK Prospective Diabetes Study Group: Efficacy of atenolol and captopril in reducing risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 39. UK Prospective Diabetes Study Group. BMJ 317: 713-720, 1998
38. Gueyffier F, Bulpitt C, Boissel JP, Schron E, Ekborn T, Fagard R, Casiglia E, Kerlikowske K, Coope J: Antihypertensive drugs in very old people: A subgroup meta-analysis of randomised controlled trials. INDANA Group. Lancet 353: 793-796, 1999
39. Assessing care of vulnerable elders-3 quality indicators. J Am Geriatr Soc 55[Suppl 2]: S464-S487, 2007
40. Heidenreich PA, Fonarow GC: Quality indicators for the care of heart failure in vulnerable elders. J Am Geriatr Soc 55[Suppl 2]: S340-S346, 2007
41. Kostis JB, Wilson AC, Freudenberger RS, Cosgrove NM, Presset SL, Davis BR, SHEP Collaborative Research Group: Long-term effect of diuretic-based therapy on fatal outcomes in subjects with isolated systolic hypertension with and without diabetes. Am J Cardiol 95: 29-35, 2005
42. Blood Pressure Lowering Treatment Trialists' Collaboration, Turnbull F, Neal B, Pfeffer M, Kostis J, Algert C, Woodward M, Chalmers J, Zanchetti A, MacMahon S: Blood pressure-dependent and independent effects of agents that inhibit the renin-angiotensin system [erratum, appears in J Hypertens 25: 1524, 2007]. J Hypertens 25: 951-998, 2007
43. Locatelli F, Pozzoni P: Chronic kidney disease in the elderly: Is it really a premise for overwhelming renal failure? Kidney Int 69: 2118-2120, 2006
44. Baraldi A, Ballestri M, Rapana R, Lucchi L, Borella P, Leonelli M, Furci L, Lusvarghi E: Acute renal failure of medical type in an elderly population. Nephrol Dial Transplant 13[Suppl 7]: 25-29, 1998
45. Kramer HJ, Nguyen QD, Curhan G, Hsu CY: Renal insufficiency in the absence of albuminuria and retinopathy among adults with type 2 diabetes mellitus. JAMA 289: 3273-3277, 2003
46. Mann JF, Gerstein HC, Yi QL, Franke J, Lornn EM, Hoogwerf BJ, Rashkow A, Yusuf S, HOPE Investigators: Progression of renal insufficiency in type 2 diabetes with and without microalbuminuria: Results of the Heart Outcomes and Prevention Evaluation (HOPE) randomized study. Am J Kidney Dis 42: 936-942, 2003
47. De Zeeuw D, Remuzzi G, Parving HH, Keane WF, Zhang Z, Shahinfar S, Snapinn S, Cooper ME, Mitch WE, Brenner BM: Albuminuria, a therapeutic target for cardiovascular protection in type 2 diabetic patients with nephropathy. Circulation 110: 921-927, 2004
48. Collins R, Armitage J, Parish S, Sleigh P, Peto R, Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: A randomised placebo-controlled trial. Lancet 361: 2005-2016, 2003
49. Tonelli M, Isles C, Curhan GC, Tonkin A, Pfeffer MA, Shepherd J, Sacks FM, Furberg C, Cobbe SM, Simes J, Craven T, West M: Effect of pravastatin on cardiovascular events in people with chronic kidney disease. Circulation 110: 1557-1563, 2004
50. Tonelli M, Keech A, Shepherd J, Sacks F, Tonkin A, Packard C, Pfeffer M, Simes J, Isles C, Furberg C, West M, Craven T, Curhan G: Effect of pravastatin in people with diabetes and chronic kidney disease. J Am Soc Nephrol 16: 3748-3754, 2005
51. Antithrombotic Trialists' Collaboration: Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ 324: 71-86, 2002
52. Hansson L, Zanchetti A, Carruthers SG, Dahlöf B, Elmfeldt D, Julius S, Ménard J, Rahn KH, Wedel H, Westerling S: Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: Principal results of the Hypertension Optimal Treatment (HOT) randomised trial. HOT Study Group. Lancet 351: 1755-1762, 1998
53. Sanchez Perales MC, Vazquez E, Garcia Cortes MJ, Borrego FJ, Borrego J, Pérez del Barrio P, Liébana A, Gil JM, Viedma G, Pérez Bañasco V: Platelet antiaggregation and hemorrhagic risk in hemodialysis [in Spanish]. Nefrologia 22: 456-462, 2002
54. Wasse H, Gillen DL, Ball AM, Kestenbaum BR, Seliger SL, Sherrard D, Stehman-Breen CO: Risk factors for upper gastrointestinal bleeding among end-stage renal disease patients. Kidney Int 64: 1455-1461, 2003
55. Cruickshank JM: Beta-blockers and diabetes: The bad guys come good. Cardiovasc Drugs Ther 16: 457-470, 2002
56. Schorr RI, Ray WA, Daugherty JR, Griffin MR: Antihypertensives and the risk of serious hypoglycemia in older persons using insulin or sulfonylureas. JAMA 278: 40-43, 1997
57. Aronow WS: Peripheral arterial disease. Geriatrics 62: 19-25, 2007
58. Abaterusso C, Pertica N, Lupo A, Ortalda V, Gambaro G: Anemia in diabetic renal failure: Is there a role for early erythropoietin treatment in preventing cardiovascular mortality? Diabetes Obes Metab December 17, 2007 [epub ahead of print]
59. Ritz E, Laville M, Bilous RW, O'Donoghue D, Scherhag A, Burger U, de Alvaro F, Anemia Correction in Diabetes Study Investigators: Target level for hemoglobin correction in patients with diabetes and CKD: Primary results of the Anemia Correction in Diabetes (ACORD) Study. Am J Kidney Dis 49: 194-207, 2007
60. Phrommintikul A, Haas SJ, Elsik M, Krum H: Mortality and target haemoglobin concentrations in anaemic patients with chronic kidney disease treated with erythropoietin: A meta-analysis. Lancet 369: 381-388, 2007
61. KDOQI clinical practice guidelines and clinical practice recommendations for anemia in chronic kidney disease. CPR 1.1. Identifying patients and initiating evaluation. Am J Kidney Dis 47[Suppl 3]: 17-27, 2006
62. KDOQI clinical practice guidelines and clinical practice recommendations; for anemia in chronic kidney disease. 2007 Update of hemoglobin target. CPG and CPR 2.1 Hemoglobin target. Am J Kidney Dis 50[Suppl 3]: 479-512, 2007
63. Loboz KK, Shenfield GM: Drug combinations and impaired renal function: The 'triple whammy.' Br J Clin Pharmacol 59: 239-243, 2005
64. Huang ES, Gorawara-Bhat R, Chin MH: Self-reported goals of older patients with type 2 diabetes mellitus. J Am Geriatr Soc 3: 306-311, 2005
65. Staessen JA, Thijs L, Gasowski J, Cells H, Fagard RH: Treatment of isolated systolic hypertension in the elderly: Further evidence from the systolic hypertension in Europe (Syst-Eur) trial. Am I Cardiol 82: 20R-22R, 1998
66. Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: Results of the HOPE study and MICRO-HOPE substudy. Heart Outcomes Prevention Evaluation Study Investigators. Lancet 355: 253-259, 2000
67. Lindholm LH, Ibsen H, Dahlöf B, Devereux RB, Beevers G, de Faire U, Fyhrquist F, Julius S, Kjeldsen SE, Kristiansson K, Lederballe-Pedersen O, Nieminen MS, Omvik P, Oparil S, Wedel H, Aurup P, Edelman J, Snapinn S, LIFE Study Group: Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): A randomised trial against atenolol. Lancet 359: 1004-1010, 2002
68. Niskanen L, Hedner T, Hansson L, Lanke J, Niklason A, CAPPP Study Group: Reduced cardiovascular morbidity and mortality in hypertensive diabetic patients on first-line therapy with an ACE inhibitor compared with a diuretic/beta-blocker-based treatment regimen: A subanalysis of the Captopril Prevention Project. Diabetes Care 24: 2091-2096, 2001
69. Trenkwalder P, Elmfeldt D, Hofman A, Lithell H, Olofsson B, Papademetriou V, Skoog I, Zanchetti A: The Study on COgnition and Prognosis in the Elderly (SCOPE): Major CV events and stroke in subgroups of patients. Blood Press 14: 31-37, 2005